REFERENCES

https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01312
Publication by Apaxen and collaborators about discovery and in-vivo efficacy of MFC-1040 in models of Pulmonary Arterial Hypertension

https://www.mdpi.com/1422-0067/19/12/4105
Publication by Apaxen and collaborators about in-vivo efficacy of MFC-1040 in models of pulmonary fibrosis

https://www.nature.com/articles/s41467-018-04581-2
Publication by Harris and Morand about the requirement of MIF for NLRP3 inflammasome activation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534811/
Publication by Scott about NLRP3 inflammasomes as therapeutic target in PAH

https://www.dovepress.com/regulation-of-the-immune-microenvironment-by-an-nlrp3-inhibitor-contri-peer-reviewed-fulltext-article-JIR
Publication by Guo and Wang about the role of NLRP3 inflammasome in right ventricular hypertrophy in models of PAH

https://pubmed.ncbi.nlm.nih.gov/31593700/
Publication by Sendler about the role of NLRP3 inflammasomes in acute pancreatitis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571497/
Publication by Gritsenko about NLRP3 inflammasomes as driving factor of inflammaging